Acquisition of anticancer drug resistance is partially associated with cancer stemness in human colon cancer cells

International Journal of Oncology

Volumn 49, Issue 6, 2016, Pages 2558-2568

  El Khoury, Flaria ^a   Corcos, Laurent ^a   Durand, Stéphanie ^a   Simon, Brigitte ^a   Le Jossic Corcos, Catherine ^a  

^a FACULTÉ DE MÉDECINE ET DES SCIENCES DE LA SANTÉ   (France)

Author keywords

Cancer stem cells; Chemotherapy; Colon cancer; Docetaxel; Oxaliplatin

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ALPHA CATENIN; ANTINEOPLASTIC AGENT; BETA CATENIN; BETA1 INTEGRIN; BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN; CD133 ANTIGEN; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DIPEPTIDYL PEPTIDASE IV; DOCETAXEL; EPHRIN RECEPTOR B2; EPITHELIAL CELL ADHESION MOLECULE; FLUOROURACIL; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 1; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; OXALIPLATIN; SURVIVIN; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; UNINDEXED DRUG; UVOMORULIN; VILLIN; WILSON DISEASE PROTEIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN; ABCB1 PROTEIN, HUMAN; ALCAM PROTEIN, HUMAN; CCND1 PROTEIN, HUMAN; DPP4 PROTEIN, HUMAN; EPHB2 PROTEIN, HUMAN; FETOPROTEIN; LEUKOCYTE ANTIGEN; MULTIDRUG RESISTANCE PROTEIN; NERVE CELL ADHESION MOLECULE; PLATINUM COMPLEX; TAXOID;

ABCG2 GENE; APOPTOSIS; ARTICLE; ATP7B GENE; CANCER RESISTANCE; CANCER STEM CELL; CELL CYCLE PHASE; CELL DIVISION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL REGENERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; COLONOSPHERE; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; CORRELATIONAL STUDY; DOWN REGULATION; DRUG SENSITIVITY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HCT116 CELL LINE; HT 29 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; MDR1 GENE; MRP2 GENE; ONCOGENE MYC; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; TUMOR SPHEROID; UPREGULATION; CELL CYCLE; CELL SURVIVAL; COLONIC NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; HCT 116 CELL LINE; HT-29 CELL LINE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTIGENS, CD; ANTIGENS, CD29; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL ADHESION MOLECULES, NEURONAL; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLONIC NEOPLASMS; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DIPEPTIDYL PEPTIDASE 4; DRUG RESISTANCE, NEOPLASM; FETAL PROTEINS; HCT116 CELLS; HT29 CELLS; HUMANS; NEOPLASTIC STEM CELLS; ORGANOPLATINUM COMPOUNDS; P-GLYCOPROTEINS; PHENOTYPE; RECEPTOR, EPHB2; TAXOIDS;

EID: 84996590156     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2016.3725     Document Type: Article

References (73)

1. Bray F, Ren JS, Masuyer E and Ferlay J: Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 132: 1133-1145, 2013.
2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136: E359-E386, 2015.
3. Wang D and Lippard SJ: Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4: 307-320, 2005.
4. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, Haegebarth A, Korving J, Begthel H, Peters PJ, et al: Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449: 1003-1007, 2007.
5. Kanwar SS, Yu Y, Nautiyal J, Patel BB and Majumdar AP: The Wnt/beta-catenin pathway regulates growth and maintenance of colonospheres. Mol Cancer 9: 212, 2010.
6. Arnould S, Hennebelle I, Canal P, Bugat R and Guichard S: Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer 39: 112-119, 2003.
7. Ringel I and Horwitz SB: Studies with RP 56976 (taxotere): A semisynthetic analogue of taxol. J Natl Cancer Inst 83: 288-291, 1991.
8. Sternberg CN, ten Bokkel Huinink WW, Smyth JF, Bruntsch V, Dirix LY, Pavlidis NA, Franklin H, Wanders S, Le Bail N and Kaye SB: Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: An EORTC Early Clinical Trials Group Study. Br J Cancer 70: 376-379, 1994.
9. Lee HH, Leake BF, Teft W, Tirona RG, Kim RB and Ho RH: Contribution of hepatic organic anion-transporting polypeptides to docetaxel uptake and clearance. Mol Cancer Ther 14: 994-1003, 2015.
10. van Herwaarden AE, Wagenaar E, van der Kruijssen CM, van Waterschoot RA, Smit JW, Song JY, van der Valk MA, van Tellingen O, van der Hoorn JW, Rosing H, et al: Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 117: 3583-3592, 2007.
11. Wils P, Phung-Ba V, Warnery A, Lechardeur D, Raeissi S, Hidalgo IJ and Scherman D: Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Pharmacol 48: 1528-1530, 1994.
12. Tsai SM, Lin CY, Wu SH, Hou LA, Ma H, Tsai LY and Hou M F: Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms. Clin Chim Acta 404: 160-165, 2009.
13. Murray S, Briasoulis E, Linardou H, Bafaloukos D and Papadimitriou C: Taxane resistance in breast cancer: Mechanisms, predictive biomarkers and circumvention strategies. Cancer Treat Rev 38: 890-903, 2012.
14. Wen K, Fu Z, Wu X, Feng J, Chen W and Qian J: Oct-4 is required for an antiapoptotic behavior of chemoresistant colorectal cancer cells enriched for cancer stem cells: Effects associated with STAT3/Survivin. Cancer Lett 333: 56-65, 2013.
15. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988, 2003.
16. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM: Identification of pancreatic cancer stem cells. Cancer Res 67: 1030-1037, 2007.
17. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB: Identification of human brain tumour initiating cells. Nature 432: 396-401, 2004.
18. O'Brien CA, Pollett A, Gallinger S and Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110, 2007.
19. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C and De Maria R: Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115, 2007.
20. Jordan CT: Cancer stem cell biology: From leukemia to solid tumors. Curr Opin Cell Biol 16: 708-712, 2004.
21. An Y and Ongkeko WM: ABCG2: The key to chemoresistance in cancer stem cells? Expert Opin Drug Metab Toxicol 5: 1529-1542, 2009.
22. D'Arcangelo M, Todaro M, Salvini J, Benfante A, Colorito ML, D'Incecco A, Landi L, Apuzzo T, Rossi E, Sani S, et al: Cancer Stem Cells Sensitivity Assay (STELLA) in patients with advanced lung and colorectal cancer: A feasibility study. PLoS One 10: e0125037, 2015.
23. Maugeri-Saccà M, Vigneri P and De Maria R: Cancer stem cells and chemosensitivity. Clin Cancer Res 17: 4942-4947, 2011.
24. Chakrabarty S: Regulation of human colon-carcinoma cell adhesion to extracellular matrix by transforming growth factor beta 1. Int J Cancer 50: 968-973, 1992.
25. Whissell G, Montagni E, Martinelli P, Hernando-Momblona X, Sevillano M, Jung P, Cortina C, Calon A, Abuli A, Castells A, et al: The transcription factor GATA6 enables self-renewal of colon adenoma stem cells by repressing BMP gene expression. Nat Cell Biol 16: 695-707, 2014.
26. Huang R, Wang G, Song Y, Tang Q, You Q, Liu Z, Chen Y, Zhang Q, Li J, Muhammand S, et al: Colorectal cancer stem cell and chemoresistant colorectal cancer cell phenotypes and increased sensitivity to Notch pathway inhibitor. Mol Med Rep 12: 2417-2424, 2015.
27. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
28. Liang CC, Park AY and Guan JL: In vitro scratch assay: A convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2: 329-333, 2007.
29. Saha A, Shree Padhi S, Roy S and Banerjee B: Method of detecting new cancer stem cell-like enrichment in development front assay (DFA). J Stem Cells 9: 235-242, 2014.
30. Myint K, Li Y, Paxton J and McKeage M: Multidrug resistance-associated protein 2 (MRP2) mediated transport of oxaliplatin-derived platinum in membrane vesicles. PLoS One 10: e0130727, 2015.
31. Buxhofer-Ausch V, Secky L, Wlcek K, Svoboda M, Kounnis V, Briasoulis E, Tzakos AG, Jaeger W and Thalhammer T: Tumorspecific expression of organic anion-transporting polypeptides: Transporters as novel targets for cancer therapy. J Drug Deliv 2013: 863539, 2013.
32. Rabik CA, Maryon EB, Kasza K, Shafer JT, Bartnik CM and Dolan ME: Role of copper transporters in resistance to platinating agents. Cancer Chemother Pharmacol 64: 133-142, 2009.
33. Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH and Pommier Y: Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 62: 4899-4902, 2002.
34. Garg A and Aggarwal BB: Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia 16: 1053-1068, 2002.
35. Yilmaz M and Christofori G: EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 28: 15-33, 2009.
36. Pang R, Law WL, Chu AC, Poon JT, Lam CS, Chow AK, Ng L, Cheung LW, Lan XR, Lan HY, et al: A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 6: 603-615, 2010.
37. Papailiou J, Bramis KJ, Gazouli M and Theodoropoulos G: Stem cells in colon cancer. A new era in cancer theory begins. Int J Colorectal Dis 26: 1-11, 2011.
38. Hermann PC, Bhaskar S, Cioffi M and Heeschen C: Cancer stem cells in solid tumors. Semin Cancer Biol 20: 77-84, 2010.
39. Wang J, Wang H, Li Z, Wu Q, Lathia JD, McLendon RE, Hjelmeland AB and Rich JN: c-Myc is required for maintenance of glioma cancer stem cells. PLoS One 3: e3769, 2008.
40. Mori R, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Tomoda K, Mori Y, Ogawa R, Katada T, Harata K, et al: Targeting beta1 integrin restores sensitivity to docetaxel of esophageal squamous cell carcinoma. Oncol Rep 20: 1345-1351, 2008.
41. Zhang H, Ozaki I, Mizuta T, Matsuhashi S, Yoshimura T, Hisatomi A, Tadano J, Sakai T and Yamamoto K: Beta 1-integrin protects hepatoma cells from chemotherapy induced apoptosis via a mitogen-activated protein kinase dependent pathway. Cancer 95: 896-906, 2002.
42. Schenk PW, Stoop H, Bokemeyer C, Mayer F, Stoter G, Oosterhuis JW, Wiemer E, Looijenga LH and Nooter K: Resistance to platinum-containing chemotherapy in testicular germ cell tumors is associated with downregulation of the protein kinase SRPK1. Neoplasia 6: 297-301, 2004.
43. Gout S, Brambilla E, Boudria A, Drissi R, Lantuejoul S, Gazzeri S and Eymin B: Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma. PLoS One 7: e46539, 2012.
44. el-Akawi Z, Abu-Hadid M, Perez R, Glavy J, Zdanowicz J, Creaven PJ and Pendyala L: Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells. Cancer Lett 105: 5-14, 1996.
45. Hall MD, Okabe M, Shen DW, Liang XJ and Gottesman MM : The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 48: 495-535, 2008.
46. Habel N, Hamidouche Z, Girault I, Patiño-García A, Lecanda F, Marie PJ and Fromigué O: Zinc chelation: A metallothionein 2A's mechanism of action involved in osteosarcoma cell death and chemotherapy resistance. Cell Death Dis 4: e874, 2013.
47. L'Espérance S, Popa I, Bachvarova M, Plante M, Patten N, Wu L, Têtu B and Bachvarov D: Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: Molecular signatures of chemoresistant tumors. Int J Oncol 29: 5-24, 2006.
48. Gottesman MM and Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427, 1993.
49. Levêque D and Jehl F: P-glycoprotein and pharmacokinetics. Anticancer Res 15: 331-336, 1995.
50. Roninson IB: Molecular mechanism of multidrug resistance in tumor cells. Clin Physiol Biochem 5: 140-151, 1987.
51. She JJ, Zhang PG, Wang X, Che XM and Wang ZM: Side population cells isolated from KATO III human gastric cancer cell line have cancer stem cell-like characteristics. World J Gastroenterol 18: 4610-4617, 2012.
52. Ceckova M, Vackova Z, Radilova H, Libra A, Buncek M and Staud F: Effect of ABCG2 on cytotoxicity of platinum drugs: Interference of EGFP. Toxicol In Vitro 22: 1846-1852, 2008.
53. Qu H, Fang L, Duan L and Long X: Expression of ABCG2 and p-glycoprotein in residual breast cancer tissue after chemotherapy and their correlation with epithelial-mesenchymal transition. Zhonghua Bing Li Xue Za Zhi 43: 236-240, 2014 (In Chinese).
54. Hinoshita E, Uchiumi T, Taguchi K, Kinukawa N, Tsuneyoshi M, Maehara Y, Sugimachi K and Kuwano M: Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. Clin Cancer Res 6: 2401-2407, 2000.
55. Tamai I: Oral drug delivery utilizing intestinal OATP transporters. Adv Drug Deliv Rev 64: 508-514, 2012.
56. Plasencia C, Martínez-Balibrea E, Martinez-Cardús A, Quinn Di, Abad A and Neamati N: Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells. Int J Oncol 29: 225-235, 2006.
57. Damia G, Guidi G and D'Incalci M: Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines. Eur J Cancer 34: 1783-1788, 1998.
58. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT and Hamilton TC: Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 63: 1311-1316, 2003.
59. Rosell R, Taron M, Barnadas A, Scagliotti G, Sarries C and Roig B: Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer. Cancer Control 10: 297-305, 2003.
60. David CJ and Manley JL: Alternative pre-mRNA splicing regulation in cancer: Pathways and programs unhinged. Genes Dev 24: 2343-2364, 2010.
61. Kim SM, Lee SY, Yuk DY, Moon DC, Choi SS, Kim Y, Han SB, Oh KW and Hong JT: Inhibition of NF-kappaB by ginsenoside Rg3 enhances the susceptibility of colon cancer cells to docetaxel. Arch Pharm Res 32: 755-765, 2009.
62. Wang CY, Cusack JC Jr, Liu R and Baldwin AS Jr: Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 5: 412-417, 1999.
63. Shen W, Pang H, Liu J, Zhou J, Zhang F, Liu L, Ma N, Zhang N, Zhang H and Liu L: Epithelial-mesenchymal transition contributes to docetaxel resistance in human non-small cell lung cancer. Oncol Res 22: 47-55, 2014.
64. Mahyar-Roemer M and Roemer K: p21 Waf1/Cip1 can protect human colon carcinoma cells against p53-dependent and p53-independent apoptosis induced by natural chemopreventive and therapeutic agents. Oncogene 20: 3387-3398, 2001.
65. Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, Gray MJ, Cheng H, Hoff PM and Ellis LM: Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 12: 4147-4153, 2006.
66. Bates RC, DeLeo MJ III and Mercurio AM: The epithelialmesenchymal transition of colon carcinoma involves expression of IL-8 and CXCR-1-mediated chemotaxis. Exp Cell Res 299: 315-324, 2004.
67. Na DC, Lee JE, Yoo JE, Oh BK, Choi GH and Park YN: Invasion and EMT-associated genes are up-regulated in B viral hepatocellular carcinoma with high expression of CD133-human and cell culture study. Exp Mol Pathol 90: 66-73, 2011.
68. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, et al: Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 104: 10158-10163, 2007.
69. Leinung M, Ernst B, Döring C, Wagenblast J, Tahtali A, Diensthuber M, Stöver T and Geissler C: Expression of ALDH1A1 and CD44 in primary head and neck squamous cell carcinoma and their value for carcinogenesis, tumor progression and cancer stem cell identification. Oncol Lett 10: 2289-2294, 2015.
70. Sullivan JP, Spinola M, Dodge M, Raso MG, Behrens C, Gao B, Schuster K, Shao C, Larsen JE, Sullivan LA, et al: Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res 70: 9937-9948, 2010.
71. Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, Kieu C, Papior P, Baeuerle PA, Munz M, et al: Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 11: 162-171, 2009.
72. Amini S, Fathi F, Mobalegi J, Sofimajidpour H and Ghadimi T: The expressions of stem cell markers: Oct4, Nanog, Sox2, nucleostemin, Bmi, Zfx, Tcl1, Tbx3, Dppa4, and Esrrb in bladder, colon, and prostate cancer, and certain cancer cell lines. Anat Cell Biol 47: 1-11, 2014.
73. Wiktorska M, Sacewicz-Hofman I, Stasikowska-Kanicka O, Danilewicz M and Niewiarowska J: Distinct inhibitory efficiency of siRNAs and DNAzymes to 1 integrin subunit in blocking tumor growth. Acta Biochim Pol 60: 77-82, 2013.